Introduction
Leishmaniasis, malaria, tuberculosis, leprosy, typhoid and listeriosis are infectious diseases which, together, cause enormous public health problems throughout the world. The etiologic agents of these diseases, Leishmania ssp., Plasmodium ssp., Mycobacterium tuberculosis, Mycobacterium leprae, Salmonella typhi / S. paratyphi or Listeria monocytogenes, respectively, are endowed with the capacity to utilize the intracellular habitat of various host cells, including macrophages, erythrocytes and liver cells. This intracellular habitat effectively protects them from antibody-mediated defence mechanisms, so that T lyrnphocytes are required for acquisition of antimicrobial protection. Protective immunity is best induced by viable vaccines, whereas soluble proteins are generally insufficient. This is not only of great academic interest, but also of apCorrespondence to: S.H.E. Kaufmann, Department of Immunology, University of Ulm, Albert-Einstein-Allee 11, D-7900 Ulm, FRG. plied interest for vaccine development. To data, only two living bacterial strains are being used as vaccines against intracellular pathogens: Mycobacterium boris BCG (Bacillus CalmetteGu4rin) [1] against tuberculosis, and Salmonella typhi Ty21a [2] against typhoid.
Despite numerous specific and unique characteristics, protective immunity against these intracellular pathogens has several aspects in common [3] [4] [5] [6] . In this review we will focus on immunity to tuberculosis and on the use of viable recombinant vaccines as multivalent carrier systems for the vaccination against various intracellular microbial infections. We will discuss new strategies to improve M. boris BCG and S. typhimurium aroAby genetic engineering, in order to evoke optimum protection.
Tuberculosis
Tuberculosis not only represents a major health threat throughout the world; it also paradigmatically exemplifies the unique role of T cells in the protection and pathogenesis of intracellular microbial infection. Worldwide, 60 million people 96 suffer from active tuberculosis, whilst annually 3 million new cases arise and 10 million people die [7] . Tuberculosis not only remains a problem in developing countries; in recent years the number of cases has dramatically increased in industrialized countries as well: 33% in Switzerland, 30% in Denmark, 28% in Italy and 12% in the USA. The rising numbers of infections with drug-resistant M. tuberculosis strains make this resurgence even more frightening [8] .
Tuberculosis is characterized by a long incubation time and chronic course of disease. The lung is not only the major port for microbial entry but also the preferred site of disease. The majority of infected individuals harbour mycobacteria within minute granulomas, where persistence is controlled by T ceils which have the key position in the interplay between host response and pathogen. In a minority of infected people, weakening of the balanced, but labile, immune system results in reactivation of silent infectious foci, leading to clinically apparent tuberculosis at a later date [9, 10] .
T cell immunity
We will briefly describe the T cell mediated immune response as it is related to infections with intracellular pathogens. The T cell system consists of three different subsets, divided according to their use of T cell receptors (TCR) and accessory molecules which interact with gene products of the Major Histocompatibility Complex (MHC) class I or class II. The TCR recognizes microbial peptides presented in a groove composed of polymorphic sections of the MHC, whereas the CD4 and CD8 accessory molecules contact monomorphic areas of the MHC class II or MHC class I products, respectively.
CD4 a//3 T cells, which are directed towards antigenic peptides plus MHC class II, are primarily helper T cells. In mice, and probably also in man, they can be further subdivided according to their cytokine production. So-called TH1 cells preferentially produce interleukin 2 (IL-2) and interferon-7 (IFN-7), whereas TH 2 cells primarily synthesize IL-4, IL-5 and IL-10 [11] . That CD4 T cells play a central role in the response to intracellular microbes is demonstrated by adoptive transfer experiments or in vivo depletion studies with monoclonal antibodies (mAbs) [12] [13] [14] [15] [16] [17] : They also cause macrophage activation, mainly by production of the cytokine IFN-y, which induces antimicrobial functions [18, 19] . In addition, CD4 T ceils often express specific cytolytic activities [20] .
CD8 a//3 T cells are primarily cytolytic, and recognize antigenic peptides in association with MHC class I gene products. The importance of CD8 T cells in the protection against intracellular microbes has been demonstrated in the mouse by phenotypic manipulations [14] and, more recently, with mutant mice deficient in the /32 microglobulin (/32m) gene and, thereby, lacking CD8 T cells [21] . M. tuberculosis-infected /32m-mutant mice rapidly succumb to the disease, their lungs showing significant cavity formation in contrast to normal littermates which are far more resistant [22] . This demonstrates that functional CD8 T cells represent a necessary component of the protective immune response to M. tuberculosis in mice. Protection of mice against L. monocytogenes infection is even more dominated by CD8 T cells, with a minor contribution by CD4 T cells. This has been established by T cell depletion and adoptive transfer experiments in mice [17, 23] . At the same time, target cell lysis caused by CD8 T cells could contribute to pathogenesis as evidenced by experimental listeriosis and leprosy studies [24, 25] . In murine salmonellosis, on the other hand, only a minor role for CD8 T cells could be demonstrated [26] [27] [28] [29] .
7/8 T cells are generally CD4-, CD8 and represent only a minor T cell population (less than 10%) in peripheral blood and lymphoid organs of mouse and man. They produce a number of cytokines and express cytolytic activities. 7/8 T cells may play a role in infections in vivo, as evidenced by the expansion of mycobacteria-reactive 7/8 T ceils after subcutaneous and aerosol immunization of mice [30] [31] [32] [33] [34] . Recent data provide indirect evidence for an a//3 T cell-independent mechanism of resistance to mycobacteria and listeriae. Thus, BCG causes progressive infection in severe combined immunodeficient (SCID) mice, but not in mice depleted of CD4 and CD8 T cells. It is likely, therefore, that this protective function depends on y/~ T cells, B ceils, or both [35] . Similarly, mutant mice deficient in a/~ T cell are as resistant as controls to early experimental L. monocytogenes infection. Probably the defect in a//3 T cell function is compensated by y/~ T ceils (Mombaerts, P., submitted).
Local immunity
Frequently the initial encounter between the host immune system and various intracellular pathogens occurs at the level of the mucosa, either in the gastro-intestinal tract or in the lung. It is, therefore, a logical goal to develop oral vaccines capable of effectively stimulating mucosal immune responses [36] . For example, M. tuberculosis, L. monocytogenes, or S. typhi/S. paratyphi/S, typhimurium enter the body via mucosal routes, whilst Leishmania ssp. and Plasmodium ssp. are directly injected into the blood during an insect bite. However, most experimental studies have focused on central immunity. It is now well appreciated that the mucosal immune system is quite different from, and independent of, the central immune system. The GALT (gutassociated lymphoid tissue) and the BALT (bronchi-associated lymphoid tissue) are closely linked, despite their histologic separation. The BALT serves as a major barrier to entry of the intracellular microorganisms, M. tuberculosis and M. boris, while the intestinal first line of defence, the GALT, is passed by the agents of food-borne diseases including L. monocytogenes and S. typhi/ S. paratyphi / S. typhimurium. The advantage of vaccines applied orally lies in the direct priming of local lymphoid cells and the strong connection between GALT and BALT [37] . Orally administered vaccine strains, therefore, will not only induce an immune response in the GALT but also in the BALT. This is important for oral, multivalent vaccines against pathogens with different routes of entry.
97

BCG
BCG was originally derived from a strain of M. bovis by attenuation through repeated subculture in bile-containing medium, until the microbes had acquired markedly reduced virulence. Since 1948 BCG has been used worldwide to vaccinate 2500 million people against tuberculosis, with negligible occurrence of side effects. BCG can be administered intradermally as a single inoculum at, or any time after, birth, and its efficacy is unaffected by maternal antibodies. Successful BCG vaccination leads to minor lesions, local self-limiting bacterial multiplication and development of delayed type hypersensitivity (DTH) against mycobacterial proteins which may persist for 5-50 years. The DTH response to tuberculin is considered to be an indicator of effective immunity.
In various controlled trials, the efficacy of BCG vaccination as a protective measure has been found to range from ineffectiveness to 80% protection [38] . Newborns are almost fully protected against meningeal tuberculosis by BCG vaccination, whereas the efficacy in adults remains questionable. Genetic variability and differing ages of the vaccinated, unique characteristics of the atypical mycobacteria and of the M. tuberculosis strains prevalent in different parts of the world, the use of different strains and doses of BCG for immunization, as well as different immunization schedules may all have contributed to the marked variation in efficacy. Most importantly, one third of the world population has already been in contact with M. tuberculosis, and in developing countries this ratio is even higher [7] . Thus, preimmunization with M. tuberculosis may have afforded a certain degree of protection which could not be further improved by BCG in 30-70% of the adults in trial regions, such as southern India. However, BCG is a potent inducer of cell-mediated immunity with low side effects and, therefore, a good antigen carrier candidate. More recently, techniques have been developed to construct genetically engineered BCG strains, and to use them as viable antigen delivery systems [39] [40] [41] . Therefore, recombinant BCG (rBCG) is not only of potential use for vaccination against tuberculosis, but could also protect against the pathogen from which the cloned gene and its antigenic product originate.
S. typhimurium aroA-
There is no existing valuable animal model for studying infection with S. typhi/S, paratyphi, the cause of typhoid in man. Therefore, much of the work towards developing novel typhoid vaccines has utilized salmonella strains virulent in mice, in particular S. typhimurium. This strain causes invasive infections in susceptible mice comparable to typhoid in man [42] . It is, however, important to note that S. typhimurium does not evoke typhoid in man and that S. typhi does not cause typhoid in mice [43] . Hoiseth and Stocker [44] described the construction of S. typhimurium strains harbouring transposon insertions in the aroA gene which encodes an enzyme involved in the aromatic amino acid synthesis pathway. A stable S. typhimurium aroA-mutant strain was subsequently isolated and found to carry a partial transposon deletion in the aroA gene. S. typhimurium aroA-received great attention as a recombinant, avirulent carrier which can be administered orally. This is because S. typhimurium strains are able to attach to, invade and persist in the GALT, which they use as a port of entry to internal lymphoid organs, where they replicate for a limited time period [45] .
Properties of BCG and S. typhimurium aroA-
BCG and S. typhimurium aroA-can survive and grow within macrophages and other professional phagocytes [3, 46] . This property is an important prerequisite for the introduction of cloned antigens into the antigen presentation pathways for T cells. Strong evidence exists to suggest that live microbes are required for the induction of effective immunity against intracellular pathogens. It has been found that a specific cytotoxic T lymphocyte (CTL) response against circumsporozoite protein of mouse malaria Plasmodium yoelii and Plasmodium berghei is induced by recombinant S. typhimurium antigen delivery systems [26] [27] [28] . Similarily, BCG is also capable of generating MHC class I restricted CTL in mice [14, 47] . The capacity of both vaccine strains to induce MHC class I restricted CD8 T cells, however, is limited and requires improvement. Next, we will discuss the amendment of BCG and S. typhimurium aroA-on the basis of antigen accessibility and presentation.
Significant differences exist between the pathways of antigen processing/presentation in the context of MHC class I or MHC class II, respectively [48, 49] . In general, MHC class II molecules primarily present peptides derived from exogenous antigens (i.e. those internalized by the antigen presenting cells from the extracellular medium, e.g. soluble protein antigens). In contrast, MHC class I molecules generally present cytoplasmic antigens, primarily synthesized by the infected cells, e.g. viral proteins [50] . Bacterial antigens, processed through, and presented by, the MHC class I molecules, are derived from microbes, such as L. monocytogenes, which actively invade the cytoplasm [51, 52] . In contrast, antigens which are derived from microorganisms persisting inside the phagolysosomal compartment, such as M. bozis and S. typhi/S, paratyphi/S, typhimurium [3, 46] , first have to be translocated through the phagolysosomal membrane by other mechanisms before they can be presented in the context of MHC class I gene products. It is important to note that MHC class II dependent antigens can be experimentally introduced into the MHC class I processing pathway [53] . Recently, Pfeifer et al. [54] proposed a novel vacuolar MHC class I processing pathway for exogenous antigens which is resistant to cycloheximide and Brefeldin A, the inhibitors of classical MHC class I processing. Importantly, this novel pathway of MHC class I presentation does not require active release of bacteria from the endosome.
Recent studies with /32m-knock out mice have emphasized the importance of an effective CD8 T cell response in M. tuberculosis infection. Similar experiments with M. bouis BCG infected mice reveal a minor role of CD8 T cells [22] . This difference in CD8 T cell dependence between M. tuberculosis and BCG may be explained as follows: M. tuberculosis antigens gain better access to the cytoplasm than BCG specific antigens, which leads to stronger MHC class I presentation. Consequently a more effective CD8 T cell response is generated by M. tuberculosis.
An important goal, regarding multivalent bacterial vaccines, is the improved accessibility of protein antigens to the cytoplasm of infected macrophages and their subsequent MHC class I presentation. In this respect, the phagolysosomal evasion of L. monocytogenes represents a mechanism of effective MHC class I presentation which could be adapted for BCG and S. typhimurium aroA-. Listeriolysin [55] , which is a member of the pore-forming sulfhydryl-activated hemolysin family with streptolysin O as prototype [56] , is essential for evasion. Synthesis of listeriolysin in an asporogenic mutant of Bacillus subtilis, for instance, results in cytoplasmic invasion and growth of B. subtilis in the macrophage-like cell line J774 [57] . The intracytoplasmic B. subtilis was detected by electron microscopy, thus strongly supporting the notion that listeriolysin is sufficient for cytoplasmic invasion.
Improvement of BCG and S. typhimurium aroAas antigen delivery systems
Although the technology of recombinant gene expression in mycobacteria and salmonellae has been successfully established [39, 40] , the major obstacle to listeriolysin activity in BCG and S. typhimurium aroA-may lie in the secretion of listeriolysin in an active form. Mycobacteria are Gram-positive bacteria, as is L. monocytogenes, but due to the highly complex, lipoid-rich cell wall structure of mycobacteria, the export machinery including signal-peptidase specificity may differ from L. monocytogenes. Yet, structural homology between BCG and Gram-positive bacterial signal peptide sequences has been reported [58, 59] . The S. typhimurium aroA-strain belongs to the Gram-negative world as does E. coli. Only a few extracellular proteins have been identified in these species [60, 61] .
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One possible strategy for expressing an active listeriolysin in S. typhimurium aroA-may be the use of the E. coli hemolysin transport system (HlyB/HlyD) [62] discussed below. Successful listeriolysin expression in BCG and S. typhimurium aroA-should improve recombinant BCG and S. typhimurium aroA-vaccines, so that they become capable of inducing potent T cell responses composed of all subsets, i.e. CD4 all3, CD8 a/fl, and y/6 T cells.
In certain instances it may be important to evoke antibody-mediated immune responses as well. For this, heterologous antigens would best be presented on the surface of the delivering organism. In particular, secretion of antibodies, particularly immunoglobulin A (IgA), could be induced through this type of antigen delivery [63] . IgA antibodies directed against surface components could inhibit the adherence to, as well as the colonization of, cells at mucosal sites of entry. In this way, local humoral immunity could interfere with host invasion by many intracellular microbes.
Delivery systems have been developed which allow expression of foreign antigens on the bacterial cell surface. For example, peptides can be expressed at sites within the E. coli outer membrane proteins LamB and PhoE [64, 65] . The latter has already been used to insert a well-characterized epitope of the 60-kDa heat shock protein of M. tuberculosis into the cell surface-exposed domain. Semipurified hybrid protein stimulated specific T cell clones [66] .
Secretion of complete protein antigens into the extracellular space of recombinant S. typhimurium aroA-could be achieved by application of the HlyB/HlyD transport machinery from E. coli [62] . Gentschev et al. [67] demonstrated the export of the L. monocytogenes p60 antigen by means of the HlyB/HlyD translocation proteins in S. typhimurium aroA-. The p60 fusion protein was both secreted and expressed on the cell surface. Immunization of mice with this construct afforded partial protection against listeriosis. The HlyB/HlyD export machinery could also be applied for translocating the listeriolysin fusion protein in S. typhimurium aroA-, using the C-terminal hemolysin-transport signal. This liste-riolysin hybrid protein should be constructed without its own N-terminal signal peptide, in order to prevent competition with the general export pathway (GEP) [68] . This GEP, however, is not compatible with the HlyB/HIyD transport system. In addition it is, therefore, necessary that the C-terminal hemolysin specific signal peptide is selectively processed, e.g. by the OmpT protease, which may be analogous to that of E. coli [69] . Appropriate strategies are available for active listeriolysin secretion by S. typhimurium aroA-constructs could introduce antigens into the MHC class I pathway more efficiently than the strains currently used. The relative importance of systems capable of delivering antigens in a cytoplasmic, surface or secreted form, respectively, for effective antimicrobial vaccination has yet to be evaluated in vivo. Secreted proteins have the potential advantage of being processed while the vaccine still replicates inside host cells. Attenuated bacteria are avirulent and, therefore, only persist for a short time period within the infected cell [70] . Subsequent to endosomal degradation, cytoplasmic antigens, such as heat shock proteins [71, 72] , will become major targets of the immune response. In contrast, intracellular pathogens, such as M. tuberculosis, persist in host cells for extremely long periods. The major advantage of secreted antigens lies in the faster kinetics of the immune response in the previously vaccinated individual independent from pathogen survival in the host. Immunity against secreted proteins [73] [74] [75] could provide protection at times when the pathogen still fully resists endosomal degradation. Only at later time points of infection, when the pathogen is efficiently degraded, cytoplasmic proteins become available and contribute to the T cell antigen recognition pattern. Consistent with this notion, a tentative relationship of cell-mediated immunity to tuberculosis with secreted, but not somatic, antigens has been observed [75, 76] .
Concluding remarks
This review has attempted to describe the major mechanisms underlying protective immunity against intracellular microorganisms, with an emphasis on recombinant vaccine strategies. The description of all possible antigens which may be expressed by these viable delivery systems, in order to protect humans against infections of global importance including those caused by Leishmania ssp., Plasmodium ssp., S. typhi/S. paratyphi, M. tuberculosis, M. leprae, was not within the goal of this review. It would be of enormous interest for a rational vaccine design to decide whether only a few microbial antigens contribute to protection or, alternatively, whether many polypeptides are of potential relevance as long as they are presented in the 'right' form. In the former case, exact characterization of the structure and function of each antigen would be of critical importance. In the latter case, understanding the antigen presentation form, i.e. secreted, surface, or somatic expression, as well as presentation through the MHC class I or MHC class II pathway, would be far more relevant. On the basis of our current knowledge we tend to favour the latter option.
